Effective Date:

Monday, June 06, 2011

New Tests and Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, June 06, 2011

New Tests - Tests recently added to the NMS Labs test menu. *New Tests are effective immediately.*

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

NMS LABS
3701 Welsh Road
Willow Grove, PA 19090
www.NMSLabs.com

New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
5448B	Amoxapine and Metabolite Confirmation, Blood							•	•	
5448SP	Amoxapine and Metabolite Confirmation, Serum/Plasma							•	•	
5448U	Amoxapine and Metabolite Confirmation, Urine							•	•	
9107B	Amoxapine and Metabolite Screen, Blood								•	
9107SP	Amoxapine and Metabolite Screen, Serum/Plasma								•	
0325B	Amoxapine and Metabolite, Blood								•	
0325SP	Amoxapine and Metabolite, Serum/Plasma								•	
5684ME	Amphetamines Confirmation (Qualitative), Meconium		•							
5920B	Antidepressant Confirmation, Blood (CSA)							•	•	
9020B	Antidepressant Screen, Blood (CSA)							•	•	
52171B	Antidepressants Confirmation Panel 2, Blood								•	
52171SP	Antidepressants Confirmation Panel 2, Serum/Plasma								•	
5450B	Antidepressants Confirmation, Blood							•	•	
5450SP	Antidepressants Confirmation, Serum/Plasma							•	•	
5450TI	Antidepressants Confirmation, Tissue							•		
5450U	Antidepressants Confirmation, Urine							•		
4655B	Antidepressants Panel 1, Blood							•	•	
4655FL	Antidepressants Panel 1, Fluid							•		
4655SP	Antidepressants Panel 1, Serum/Plasma							•	•	
4655TI	Antidepressants Panel 1, Tissue							•		
4655U	Antidepressants Panel 1, Urine							•		
8700B	Antidepressants Panel, Blood							•	•	
8700FL	Antidepressants Panel, Fluid							•		
8700SP	Antidepressants Panel, Serum/Plasma							•	•	
8700TI	Antidepressants Panel, Tissue							•		
8700U	Antidepressants Panel, Urine							•		
9022B	Antidepressants Screen - Expanded, Blood				•	•			•	
9022SP	Antidepressants Screen - Expanded, Serum/Plasma				•	•			•	

New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
9022U	Antidepressants Screen - Expanded, Urine				•	•				
9431B	Antidepressants Screen, Blood							•	•	
9431SP	Antidepressants Screen, Serum/Plasma							•	•	
9431TI	Antidepressants Screen, Tissue							•		
9431U	Antidepressants Screen, Urine							•		
5651ME	Barbiturates Confirmation (Qualitative), Meconium		•							
5641ME	Benzodiazepines Confirmation (Qualitative), Meconium		•							
0820SP	Busulfan, Serum/Plasma	•								
5646ME	Cannabinoids Confirmation (Qualitative), Meconium		•							
9136SP	Chlorpromazine Screen, Serum/Plasma				•					
52023B	Clozapine and Metabolite Confirmation, Blood (Forensic)			•						
53023B	Clozapine and Metabolite Confirmation, Blood (Forensic)			•						
52023FL	Clozapine and Metabolite Confirmation, Fluid (Forensic)			•						
53023FL	Clozapine and Metabolite Confirmation, Fluid (Forensic)			•						
52023SP	Clozapine and Metabolite Confirmation, Serum/Plasma (Forensic)			•						
53023SP	Clozapine and Metabolite Confirmation, Serum/Plasma (Forensic)			•						
52023TI	Clozapine and Metabolite Confirmation, Tissue (Forensic)			•						
53023TI	Clozapine and Metabolite Confirmation, Tissue (Forensic)			•						
52023U	Clozapine and Metabolite Confirmation, Urine (Forensic)			•						
53023U	Clozapine and Metabolite Confirmation, Urine (Forensic)			•						
5637ME	Cocaine and Metabolites Confirmation (Qualitative), Meconium		•							
54223B	Drug Impaired Driving/DRE Toxicology Clozapine and Metabolite Confirmation, Blood (Forensic)			•						
54223U	Drug Impaired Driving/DRE Toxicology Clozapine and Metabolite Confirmation, Urine (Forensic)			•						

Effective Date:

Monday, June 06, 2011

New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
1898B	Drug and Alcohol Screen - PA Police, Blood (Forensic)									•
1899B	Drug and Alcohol Screen - PA Police, Blood (Forensic)									•
1899SP	Drug and Alcohol Screen - PA Police, Serum/Plasma (Forensic)									•
4666SP	Duloxetine, Serum/Plasma					•				
2075B	Fioricet®, Blood		•							
2075FL	Fioricet®, Fluid		•							
2075SP	Fioricet®, Serum/Plasma		•							
2075TI	Fioricet®, Tissue		•							
2075U	Fioricet®, Urine		•							
8755B	Hallucinogens Screen - Expanded, Blood				•					
8755SP	Hallucinogens Screen - Expanded, Serum/Plasma				•					
8755U	Hallucinogens Screen - Expanded, Urine				•					
2276B	Heroin - Free (Unconjugated), Blood						•			
2588B	MDPV Stimulant Designer Drug Test, Blood	•								
2588SP	MDPV Stimulant Designer Drug Test, Serum/Plasma	•								
2588U	MDPV Stimulant Designer Drug Test, Urine	•								
2615B	Mephedrone Stimulant Designer Drug Test, Blood	•								
2615SP	Mephedrone Stimulant Designer Drug Test, Serum/Plasma	•								
2615U	Mephedrone Stimulant Designer Drug Test, Urine	•								
5682ME	Methadone and Metabolite Confirmation (Qualitative), Meconium		•							
5645ME	Opiates - Total (Conjugated/Unconjugated) Confirmation (Qualitative), Meconium		•							
5657ME	Phencyclidine Confirmation (Qualitative), Meconium		•							
5633ME	Propoxyphene and Metabolite Confirmation (Qualitative), Meconium		•							
5960B	Synthetic Cannabinoids Confirmation, Blood (Forensic)						•			
9561B	Synthetic Cannabinoids Screen (Qualitative), Blood (Forensic)									•

Effective Date:

Monday, June 06, 2011

New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
9560B	Synthetic Cannabinoids Screen, Blood (Forensic)						•			
4780SP	Vitamin B3 (Niacin and Metabolites), Serum/Plasma								•	

NMS LABS
3701 Welsh Road
Willow Grove, PA 19090
www.NMSLabs.com

New Tests and Test Updates

New Tests

0820SP Busulfan, Serum/Plasma — Effective Immediately

Scope of Analysis:	Busulfan [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Therapeutic Drug Monitoring; The test is an analytical service for the quantification of busulfan in a specimen. It does not provide an area-under-the-curve (AUC) calculation, busulfan clearance information or a recommendation on adjustment to dosing.
Category:	Antineoplastic
Specimen Requirements:	2 mL Serum or Plasma
Minimum Volume:	0.7 mL
Special Handling:	Collect 4 mL of blood in Green top tube (Sodium Heparin). Blood samples should be placed on wet ice immediately after collection. Centrifuge at 4 degrees Celcius within 1 hour and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. The plasma, harvested into appropriate storage tube should be frozen immediately at -20 degrees Celcius and shipped frozen on dry ice.
Specimen Container:	Plastic container (preservative-free)
Transport Temperature:	Frozen
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature. Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: Not Stable Refrigerated: 7 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Monday 2nd Shift 3 days (after set-up)
CPT Code:	83789

Compound Name / Alias	Units	RL	Reference Comment
Busulfan Busulfex®; Myleran®	ng/mL	10	The peak plasma concentrations following single oral administration of 2 mg and 4 mg busulfan were 30 ng/mL and 68 ng/mL, respectively. The mean steady-state peak plasma concentration following a 0.8 mg/kg infusion four times daily for four days (n=59) was 1200 ng/mL (range 490 - 1600 ng/mL).

2588B MDPV Stimulant Designer Drug Test, Blood — Effective Immediately

Scope of Analysis:	MDPV [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Drug of Abuse Monitoring
Category:	Stimulant
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: 21 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

New Tests and Test Updates

New Tests

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday 2nd Shift 3 days (after set-up)
CPT Code: 83789

Compound Name / Alias	Units	RL	Reference Comment
MDPV 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylpentan-1-one; Bath salts; MDPK; Magic; Mtv; Peevee; Super Coke; methylenedioxypyrovalerone	ng/mL	10	MDPV is a synthetic stimulant reported to have effects similar to methylphenidate at low doses and cocaine at high doses. Desired outcomes following use include increased energy and sociability, increased concentration, psychedelic effects and sexual stimulation. Based on an in vitro human liver microsome study, 80% of MDPV may remain unchanged in the urine, while 7% is metabolized to catechol pyrovalerone and 10% to methylcatechol pyrovalerone. Reported adverse effects include insomnia, severe agitation/anxiety, panic attacks, kidney pain, stomach cramps, tachycardia, hypertension, dilated pupils, headache, tinnitus, and peripheral neuropathies and dizziness.

2588SP MDPV Stimulant Designer Drug Test, Serum/Plasma **Effective Immediately**

Scope of Analysis: MDPV [LC-MS/MS]
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Drug of Abuse Monitoring
Category: Stimulant
Specimen Requirements: 1 mL Serum or Plasma
Minimum Volume: 0.4 mL
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Specimen Container: Plastic container (preservative-free)
Transport Temperature: Frozen
Light Protection: Not Required
Rejection Criteria: Received Room Temperature. Received Refrigerated. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: Not Stable
Refrigerated: 2 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday 2nd Shift 3 days (after set-up)
CPT Code: 83789

Compound Name / Alias	Units	RL	Reference Comment
MDPV 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylpentan-1-one; Bath salts; MDPK; Magic; Mtv; Peevee; Super Coke; methylenedioxypyrovalerone	ng/mL	10	MDPV is a synthetic stimulant reported to have effects similar to methylphenidate at low doses and cocaine at high doses. Desired outcomes following use include increased energy and sociability, increased concentration, psychedelic effects and sexual stimulation. Based on an in vitro human liver microsome study, 80% of MDPV may remain unchanged in the urine, while 7% is metabolized to catechol pyrovalerone and 10% to methylcatechol pyrovalerone. Reported adverse effects include insomnia, severe agitation/anxiety, panic attacks, kidney pain, stomach cramps, tachycardia, hypertension, dilated pupils, headache, tinnitus, and peripheral neuropathies and dizziness.

New Tests and Test Updates

New Tests

2588U MDPV Stimulant Designer Drug Test, Urine — Effective Immediately

Scope of Analysis:	MDPV [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Drug of Abuse Monitoring
Category:	Stimulant
Specimen Requirements:	1 mL Urine
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Plastic container (preservative-free)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Monday 2nd Shift 3 days (after set-up)
CPT Code:	83789

Compound Name / Alias	Units	RL	Reference Comment
MDPV 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylpentan-1-one; Bath salts; MDPK; Magic; Mtv; Peevee; Super Coke; methylenedioxypyrovalerone	ng/mL	10	MDPV is a synthetic stimulant reported to have effects similar to methylphenidate at low doses and cocaine at high doses. Desired outcomes following use include increased energy and sociability, increased concentration, psychedelic effects and sexual stimulation. Based on an in vitro human liver microsome study, 80% of MDPV may remain unchanged in the urine, while 7% is metabolized to catechol pyrovalerone and 10% to methylcatechol pyrovalerone. Reported adverse effects include insomnia, severe agitation/anxiety, panic attacks, kidney pain, stomach cramps, tachycardia, hypertension, dilated pupils, headache, tinnitus, and peripheral neuropathies and dizziness.

2615B Mephedrone Stimulant Designer Drug Test, Blood — Effective Immediately

Scope of Analysis:	Mephedrone [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Drug of Abuse Monitoring
Category:	Stimulant
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)

New Tests and Test Updates

New Tests

Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 1 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday 2nd Shift 3 days (after set-up)
CPT Code: 83789

Compound Name / Alias	Units	RL	Reference Comment
Mephedrone 4-MMC; 4-methyl-N-methcathinone; 4-methylmethcathinone; Meow Meow; Sunshine; Synthetic stimulant	ng/mL	20	Mephedrone is a psychoactive compound that is structurally related to amphetamine. It is abused for its perceived 'ecstasy like' effects of euphoria, excitement and alertness. Reported adverse effects include peripheral vasoconstriction resulting in a bruised appearance on the arms and legs, loss of appetite, poor concentration, increased heart rate, sweating with an odor, and dilation of the pupils. In two fatalities where mephedrone intoxication was determined to be the cause of death blood concentrations were 22000 ng/mL and 3300 ng/mL.

2615SP Mephedrone Stimulant Designer Drug Test, Serum/Plasma — **Effective Immediately**

Scope of Analysis: Mephedrone [LC-MS/MS]
Method(s): High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose: Drug of Abuse Monitoring
Category: Stimulant
Specimen Requirements: 1 mL Serum or Plasma
Minimum Volume: 0.4 mL
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Specimen Container: Plastic container (preservative-free)
Transport Temperature: Refrigerated
Light Protection: Not Required
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT: Monday 2nd Shift 3 days (after set-up)
CPT Code: 83789

Compound Name / Alias	Units	RL	Reference Comment
Mephedrone 4-MMC; 4-methyl-N-methcathinone; 4-methylmethcathinone; Meow Meow; Sunshine; Synthetic stimulant	ng/mL	20	Mephedrone is a psychoactive compound that is structurally related to amphetamine. It is abused for its perceived 'ecstasy like' effects of euphoria, excitement and alertness. Reported adverse effects include peripheral vasoconstriction resulting in a bruised appearance on the arms and legs, loss of appetite, poor concentration, increased heart rate, sweating with an odor, and dilation of the pupils. In two fatalities where mephedrone intoxication was determined to be the cause of death blood concentrations were 22000 ng/mL and 3300 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

New Tests and Test Updates

New Tests

2615U Mephedrone Stimulant Designer Drug Test, Urine **Effective Immediately**

Scope of Analysis:	Mephedrone [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Drug of Abuse Monitoring
Category:	Stimulant
Specimen Requirements:	1 mL Urine
Minimum Volume:	0.22 mL
Special Handling:	None
Specimen Container:	Plastic container (preservative-free)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Monday 2nd Shift 3 days (after set-up)
CPT Code:	83789

Compound Name / Alias	Units	RL	Reference Comment
Mephedrone 4-MMC; 4-methyl-N-methcathinone; 4-methylmethcathinone; Meow Meow; Sunshine; Synthetic stimulant	ng/mL	200	Mephedrone is a psychoactive compound that is structurally related to amphetamine. It is abused for its perceived 'ecstasy like' effects of euphoria, excitement and alertness. Reported adverse effects include peripheral vasoconstriction resulting in a bruised appearance on the arms and legs, loss of appetite, poor concentration, increased heart rate, sweating with an odor, and dilation of the pupils.

New Tests and Test Updates

Test Changes

5448B Amoxapine and Metabolite Confirmation, Blood

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC (82492): Amoxapine, 8-Hydroxy Amoxapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	[Reference comment removed]
8-Hydroxy Amoxapine	ng/mL	Optimal serum therapeutic range (Amoxapine plus active metabolite): 200 - 400 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

5448SP Amoxapine and Metabolite Confirmation, Serum/Plasma

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC (82492): Amoxapine, 8-Hydroxy Amoxapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	[Reference comment removed]
8-Hydroxy Amoxapine	ng/mL	Optimal serum therapeutic range (Amoxapine plus active metabolite): 200 - 400 ng/mL.

5448U Amoxapine and Metabolite Confirmation, Urine

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC (82492): Amoxapine, 8-Hydroxy Amoxapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	[Reference comment removed]
8-Hydroxy Amoxapine	ng/mL	No reference data available.

9107B Amoxapine and Metabolite Screen, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): HPLC (80100): Amoxapine, 8-Hydroxy Amoxapine

New Tests and Test Updates

Test Changes

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	[Reference comment removed]
8-Hydroxy Amoxapine	ng/mL	Optimal serum therapeutic range (Amoxapine plus active metabolite): 200 - 400 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

9107SP Amoxapine and Metabolite Screen, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): HPLC (80100): Amoxapine, 8-Hydroxy Amoxapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	[Reference comment removed]
8-Hydroxy Amoxapine	ng/mL	Optimal serum therapeutic range (Amoxapine plus active metabolite): 200 - 400 ng/mL.

0325B Amoxapine and Metabolite, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): HPLC (82492): Amoxapine, 8-Hydroxy Amoxapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	[Reference comment removed]
8-Hydroxy Amoxapine	ng/mL	Optimal serum therapeutic range (Amoxapine plus active metabolite): 200 - 400 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

0325SP Amoxapine and Metabolite, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): HPLC (82492): Amoxapine, 8-Hydroxy Amoxapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	[Reference comment removed]

New Tests and Test Updates

Test Changes

Compound Name	Units	Reference Comment
8-Hydroxy Amoxapine	ng/mL	Optimal serum therapeutic range (Amoxapine plus active metabolite): 200 - 400 ng/mL.

5684ME Amphetamines Confirmation (Qualitative), Meconium

Summary of Changes: Test Name was changed.

5920B Antidepressant Confirmation, Blood (CSA)

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC/MS (80102): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine, Cyclobenzaprine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

9020B Antidepressant Screen, Blood (CSA)

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC (82492): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine, Cyclobenzaprine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

52171B Antidepressants Confirmation Panel 2, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): GC (82492): Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Trimipramine, Desmethyltrimipramine, Protriptyline, Maprotiline, Amoxapine

New Tests and Test Updates

Test Changes

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

52171SP Antidepressants Confirmation Panel 2, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): GC (82492): Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Trimipramine, Desmethyltrimipramine, Protriptyline, Maprotiline, Amoxapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL.

5450B Antidepressants Confirmation, Blood

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC/MS (80102): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

5450SP Antidepressants Confirmation, Serum/Plasma

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC/MS (80102): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL.

New Tests and Test Updates

Test Changes

5450TI Antidepressants Confirmation, Tissue

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC/MS (80103, 80102): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/g	

5450U Antidepressants Confirmation, Urine

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC/MS (80102): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	

4655B Antidepressants Panel 1, Blood

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC (82492): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

4655FL Antidepressants Panel 1, Fluid

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC (82492): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	

New Tests and Test Updates

Test Changes

4655SP Antidepressants Panel 1, Serum/Plasma

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC (82492): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL.

4655TI Antidepressants Panel 1, Tissue

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC (80103, 82492): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/g	

4655U Antidepressants Panel 1, Urine

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC (82492): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	

8700B Antidepressants Panel, Blood

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC & GC/MS (82542): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

New Tests and Test Updates

Test Changes

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

8700FL Antidepressants Panel, Fluid

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC & GC/MS (82542): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	

8700SP Antidepressants Panel, Serum/Plasma

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC & GC/MS (82542): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL.

8700TI Antidepressants Panel, Tissue

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC & GC/MS (80103, 82542): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/g	

8700U Antidepressants Panel, Urine

Summary of Changes: Units were changed.

New Tests and Test Updates

Test Changes

Scope of Analysis: GC & GC/MS (82542): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine
Method (CPT Code)

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	

9022B Antidepressants Screen - Expanded, Blood

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 6 mL Blood
Transport Temperature: Frozen
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Ensure that container remains tightly sealed.
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 14 day(s)
Scope of Analysis: LC-MS/MS (80100): Paroxetine, Sertraline, Amoxapine, Clomipramine, Desipramine, Desmethylclomipramine, Desmethyltrimipramine, Imipramine, Maprotiline, Protriptyline, Trimipramine, Amitriptyline, Desmethyldoxepin, Doxepin, Fluoxetine, Mirtazapine, Norfluoxetine, Nortriptyline, Trazodone, Citalopram / Escitalopram, Fluvoxamine, Nefazodone, Bupropion, Hydroxybupropion, Duloxetine, O-Desmethylvenlafaxine, Venlafaxine
Method (CPT Code)

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

9022SP Antidepressants Screen - Expanded, Serum/Plasma

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Stability was changed.
Reference Comment was changed.

New Tests and Test Updates

Test Changes

Specimen Requirements:	6 mL Serum or Plasma
Transport Temperature:	Frozen
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Yes
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Ensure that container remains tightly sealed.
Rejection Criteria:	Not received Light Protected. Received Room Temperature. Received Refrigerated. Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80100): Paroxetine, Sertraline, Amoxapine, Clomipramine, Desipramine, Desmethylclomipramine, Desmethyltrimipramine, Imipramine, Maprotiline, Protriptyline, Trimipramine, Amitriptyline, Desmethyldoxepin, Doxepin, Fluoxetine, Mirtazapine, Norfluoxetine, Nortriptyline, Trazodone, Citalopram / Escitalopram, Fluvoxamine, Nefazodone, Bupropion, Hydroxybupropion, Duloxetine, O-Desmethylvenlafaxine, Venlafaxine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL.

9022U Antidepressants Screen - Expanded, Urine

Summary of Changes:	Specimen Requirements (Transport Temperature) were changed. Stability was changed.

Specimen Requirements:	6 mL Urine
Transport Temperature:	Frozen
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 14 day(s)

9431B Antidepressants Screen, Blood

Summary of Changes:	Reference Comment was changed. Units were changed.
Scope of Analysis: Method (CPT Code)	GC (82492): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

New Tests and Test Updates

Test Changes

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

9431SP Antidepressants Screen, Serum/Plasma

Summary of Changes: Reference Comment was changed.
Units were changed.

Scope of Analysis: Method (CPT Code): GC (82492): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	Reported serum concentrations following a 300 mg daily regimen ranged from 17 - 93 ng/mL.

9431TI Antidepressants Screen, Tissue

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC (80103, 82492): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/g	

9431U Antidepressants Screen, Urine

Summary of Changes: Units were changed.

Scope of Analysis: Method (CPT Code): GC (82492): Amitriptyline, Nortriptyline, Clomipramine, Desmethylclomipramine, Imipramine, Desipramine, Doxepin, Desmethyldoxepin, Trimipramine, Desmethyltrimipramine, Fluoxetine, Norfluoxetine, Protriptyline, Maprotiline, Trazodone, Amoxapine, Tranylcypromine, Venlafaxine, Mirtazapine

Compound Name	Units	Reference Comment
Amoxapine	ng/mL	

5651ME Barbiturates Confirmation (Qualitative), Meconium

Summary of Changes: Test Name was changed.

5641ME Benzodiazepines Confirmation (Qualitative), Meconium

New Tests and Test Updates

Test Changes

Summary of Changes: Test Name was changed.

5646ME Cannabinoids Confirmation (Qualitative), Meconium

Summary of Changes: Test Name was changed.

9136SP Chlorpromazine Screen, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements:	5 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test.
Light Protection:	Not Required
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).

52023B Clozapine and Metabolite Confirmation, Blood (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): Clozapine, Norclozapine

53023B Clozapine and Metabolite Confirmation, Blood (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): Clozapine, Norclozapine

52023FL Clozapine and Metabolite Confirmation, Fluid (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): Clozapine, Norclozapine

53023FL Clozapine and Metabolite Confirmation, Fluid (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): Clozapine, Norclozapine

New Tests and Test Updates

Test Changes

52023SP Clozapine and Metabolite Confirmation, Serum/Plasma (Forensic)

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (83789)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Clozapine, Norclozapine

53023SP Clozapine and Metabolite Confirmation, Serum/Plasma (Forensic)

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (83789)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Clozapine, Norclozapine

52023TI Clozapine and Metabolite Confirmation, Tissue (Forensic)

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (80103, 83789)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80103, 83789): Clozapine, Norclozapine

53023TI Clozapine and Metabolite Confirmation, Tissue (Forensic)

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (80103, 83789)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80103, 83789): Clozapine, Norclozapine

52023U Clozapine and Metabolite Confirmation, Urine (Forensic)

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (83789)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Clozapine, Norclozapine

53023U Clozapine and Metabolite Confirmation, Urine (Forensic)

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (83789)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Clozapine, Norclozapine

5637ME Cocaine and Metabolites Confirmation (Qualitative), Meconium

Summary of Changes:	Test Name was changed.

54223B Drug Impaired Driving/DRE Toxicology Clozapine and Metabolite Confirmation, Blood (Forensic)

New Tests and Test Updates

Test Changes

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): Clozapine, Norclozapine

54223U Drug Impaired Driving/DRE Toxicology Clozapine and Metabolite Confirmation, Urine (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): Clozapine, Norclozapine

4666SP Duloxetine, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 12 month(s)

2075B Fioricet®, Blood

Summary of Changes: Test Name was changed.

2075FL Fioricet®, Fluid

Summary of Changes: Test Name was changed.

2075SP Fioricet®, Serum/Plasma

Summary of Changes: Test Name was changed.

2075TI Fioricet®, Tissue

Summary of Changes: Test Name was changed.

2075U Fioricet®, Urine

Summary of Changes: Test Name was changed.

8755B Hallucinogens Screen - Expanded, Blood

Summary of Changes: Specimen Requirements were changed.

New Tests and Test Updates

Test Changes

Specimen Requirements:	10 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Yes
Special Handling:	Glass containers are not acceptable.
Rejection Criteria:	Not received Light Protected. Glass container.

8755SP Hallucinogens Screen - Expanded, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed.

Specimen Requirements:	10 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Yes
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Glass containers are not acceptable. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Not received Light Protected. Glass container. Polymer gel separation tube (SST or PST).

8755U Hallucinogens Screen - Expanded, Urine

Summary of Changes:	Specimen Requirements were changed.

Specimen Requirements:	10 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Yes
Special Handling:	Glass containers are not acceptable.
Rejection Criteria:	Not received Light Protected. Glass container.

2276B Heroin - Free (Unconjugated), Blood

Summary of Changes:	Scope of Analysis was changed. Morphine (Unconjugated) was changed to Morphine - Free 6-Monoacetylmorphine (Unconjugated) was changed to 6-Monoacetylmorphine - Free Diacetylmorphine was changed to Diacetylmorphine - Free

Scope of Analysis: Method (CPT Code)	GC/MS (83925): Morphine - Free, 6-Monoacetylmorphine - Free, Diacetylmorphine - Free

New Tests and Test Updates

Test Changes

5682ME Methadone and Metabolite Confirmation (Qualitative), Meconium

Summary of Changes: Test Name was changed.

5645ME Opiates - Total (Conjugated/Unconjugated) Confirmation (Qualitative), Meconium

Summary of Changes: Test Name was changed.

5657ME Phencyclidine Confirmation (Qualitative), Meconium

Summary of Changes: Test Name was changed.

5633ME Propoxyphene and Metabolite Confirmation (Qualitative), Meconium

Summary of Changes: Test Name was changed.

5960B Synthetic Cannabinoids Confirmation, Blood (Forensic)

Summary of Changes: Scope of Analysis was changed.
JWH-019 was added.

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): JWH-018, JWH-073, JWH-250, JWH-019

Compound Name	Units	Reference Comment
JWH-019	ng/mL	JWH-019 is a synthetic cannabinoid that may be used as an alternative to cannabis. No information is available on the metabolism of JWH-019.

9560B Synthetic Cannabinoids Screen, Blood (Forensic)

Summary of Changes: Scope of Analysis was changed.
JWH-019 was added.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80100): JWH-018, JWH-073, JWH-250, JWH-019

Compound Name	Units	Reference Comment
JWH-019	ng/mL	JWH-019 is a synthetic cannabinoid that may be used as an alternative to cannabis. No information is available on the metabolism of JWH-019.

4780SP Vitamin B3 (Niacin and Metabolites), Serum/Plasma

New Tests and Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (84591): Nicotinic Acid, Nicotinamide, Nicotinuric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Nicotinic Acid	ng/mL	Nicotinic acid occurs naturally in plants and animals and is also added to many foods as a vitamin supplement. Due to the large variability in the metabolism of nicotinic acid, the dosing preparation used (immediate-release vs. extended-release), and the mg doses used, the serum concentrations may range from less than 10 ng/mL to about 30,000 ng/mL. After oral administration of an immediate-release tablet, peak plasma concentrations are achieved in 30 to 60 min; after oral administration of an extended-release capsule, peak plasma concentrations occur in 4 to 5 hours. The plasma half-life of nicotinic acid is about 1 hour. In one study, fasting plasma concentrations were reported to be approximately 10 ng/mL. In another study it was reported that the administration of a single 1000 mg extended-release tablet resulted in mean nicotinic acid concentrations of less than 50 ng/mL. The administration of multiple oral doses of nicotinic acid (for a total of 2000 mg) resulted in the following mean peak nicotinic acid plasma concentrations: 25 mg every 10 min. for 80 doses (over 13 hours): 1100 ng/mL 50 mg every 10 min. for 40 doses (over 6.5 hours): 5400 ng/mL 100 mg every 10 min. for 20 doses (over 3 hours): 29000 ng/mL This test should be considered as a therapeutic drug monitoring/toxcicological test associated with niacin (Vitamin B3) supplementation. Care should be taken in the use of this test for basal Vitamin B3 determination. The supplied reference comment does not reflect normal, endogenous Vitamin B3 concentrations.
Nicotinamide	ng/mL	Nicotinamide is a metabolite of nicotinic acid, is the common form of niacin included in vitamin preparations and is also added to many foods as a vitamin supplement. Due to the large variability in the metabolism of nicotinic acid, plasma concentrations of this metabolite also are variable.

New Tests and Test Updates

Test Changes

Compound Name	Units	Reference Comment
		In one study, fasting plasma concentrations were reported to be approximately 40 ng/mL. In another study it was reported that the administration of a single 1000 mg extended-release tablet of nicotinic acid resulted in a mean peak nicotinamide concentration of 400 ng/mL between 5 and 10 hours post dose, decreasing to about 100 ng/mL by 16 hours post dose. The administration of multiple oral doses of nicotinic acid (for a total of 2000 mg) resulted in the following mean peak nicotinamide plasma concentrations: 25 mg every 10 min. for 80 doses (over 13 hours): 1300 ng/mL 50 mg every 10 min. for 40 doses (over 6.5 hours): 2300 ng/mL 100 mg every 10 min. for 20 doses (over 3 hours): 2000 ng/mL This test should be considered as a therapeutic drug monitoring/toxcicological test associated with niacin (Vitamin B3) supplementation. Care should be taken in the use of this test for basal Vitamin B3 determination. The supplied reference comment does not reflect normal, endogenous Vitamin B3 concentrations.
Nicotinuric Acid	ng/mL	Nicotinuric acid is a metabolite of nicotinic acid and nicotinamide. Due to the large variability in the metabolism of nicotinic acid and nicotinamide, plasma concentrations of this metabolite also are variable. In one study it was reported that the administration of a single 1000 mg extended-release tablet of nicotinic acid resulted in a mean peak nicotinuric acid concentration of over 1000 ng/mL within 2 hours post dose, decreasing to less than 200 ng/mL by 6 hours and less than 50 ng/mL by 12 hours post dose. The administration of multiple oral doses of nicotinic acid (for a total of 2000 mg) resulted in the following mean peak nicotinuric acid plasma concentrations: 25 mg every 10 min. for 80 doses (over 13 hours): 950 ng/mL 50 mg every 10 min. for 40 doses (over 6.5 hours): 2300 ng/mL 100 mg every 10 min. for 20 doses (over 3 hours): 5100 ng/mL

New Tests and Test Updates

Test Changes

Compound Name	Units	Reference Comment
		This test should be considered as a therapeutic drug monitoring/toxcicological test associated with niacin (Vitamin B3) supplementation. Care should be taken in the use of this test for basal Vitamin B3 determination. The supplied reference comment does not reflect normal, endogenous Vitamin B3 concentrations.

New Tests and Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
1898B	Drug and Alcohol Screen - PA Police, Blood (Forensic)	8070B - Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Blood (Forensic)
1899B	Drug and Alcohol Screen - PA Police, Blood (Forensic)	8070B - Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Blood (Forensic)
1899SP	Drug and Alcohol Screen - PA Police, Serum/Plasma (Forensic)	8070B - Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Blood (Forensic)
9561B	Synthetic Cannabinoids Screen (Qualitative), Blood (Forensic)	9560B - Synthetic Cannabinoids Screen, Blood (Forensic)